Excellent! Worth noting that whilst only 3/11 patients show a 50% or greater reduction at the midpoint, this is a dose escalation trial so the midpoint is determined as being a dose of 90mg, with the dosage then increasing to 150mg and then finally 240mg.
One patient who had completed the study had a 66% reduction in proteinuria at only a 90mg dose!
Lets see what the market thinks here today and overnight as I bet a few Retrophin investors are keeping an eye out here.
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $333.0M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.0¢ | 55.0¢ | $141.6K | 255.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 40651 | 54.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 52442 | 2 |
View Market Depth
| Last trade - 10.50am 18/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |